| pubmed-article:16565562 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:16565562 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:16565562 | lifeskim:mentions | umls-concept:C0042510 | lld:lifeskim |
| pubmed-article:16565562 | lifeskim:mentions | umls-concept:C0023660 | lld:lifeskim |
| pubmed-article:16565562 | lifeskim:mentions | umls-concept:C1707455 | lld:lifeskim |
| pubmed-article:16565562 | lifeskim:mentions | umls-concept:C2350374 | lld:lifeskim |
| pubmed-article:16565562 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:16565562 | pubmed:dateCreated | 2006-3-27 | lld:pubmed |
| pubmed-article:16565562 | pubmed:abstractText | Although nifekalant is a class III antiarrhythmic agent without negative inotropic activity, its effect in patients with shock-refractory ventricular fibrillation remains unclear. | lld:pubmed |
| pubmed-article:16565562 | pubmed:language | eng | lld:pubmed |
| pubmed-article:16565562 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16565562 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:16565562 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16565562 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16565562 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16565562 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16565562 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16565562 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:16565562 | pubmed:month | Apr | lld:pubmed |
| pubmed-article:16565562 | pubmed:issn | 1346-9843 | lld:pubmed |
| pubmed-article:16565562 | pubmed:author | pubmed-author:SuzukiNoriyuk... | lld:pubmed |
| pubmed-article:16565562 | pubmed:author | pubmed-author:UmemuraSatosh... | lld:pubmed |
| pubmed-article:16565562 | pubmed:author | pubmed-author:KosugeTakayuk... | lld:pubmed |
| pubmed-article:16565562 | pubmed:author | pubmed-author:HibiKiyoshiK | lld:pubmed |
| pubmed-article:16565562 | pubmed:author | pubmed-author:SumitaShinich... | lld:pubmed |
| pubmed-article:16565562 | pubmed:author | pubmed-author:KimuraKazuoK | lld:pubmed |
| pubmed-article:16565562 | pubmed:author | pubmed-author:KosugeMasamiM | lld:pubmed |
| pubmed-article:16565562 | pubmed:author | pubmed-author:SugiyamaMitsu... | lld:pubmed |
| pubmed-article:16565562 | pubmed:author | pubmed-author:EbinaToshiaki... | lld:pubmed |
| pubmed-article:16565562 | pubmed:author | pubmed-author:MoriwakiYoshi... | lld:pubmed |
| pubmed-article:16565562 | pubmed:author | pubmed-author:TaharaYoshioY | lld:pubmed |
| pubmed-article:16565562 | pubmed:author | pubmed-author:ToyamaHideshi... | lld:pubmed |
| pubmed-article:16565562 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:16565562 | pubmed:volume | 70 | lld:pubmed |
| pubmed-article:16565562 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:16565562 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:16565562 | pubmed:pagination | 442-6 | lld:pubmed |
| pubmed-article:16565562 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:16565562 | pubmed:meshHeading | pubmed-meshheading:16565562... | lld:pubmed |
| pubmed-article:16565562 | pubmed:meshHeading | pubmed-meshheading:16565562... | lld:pubmed |
| pubmed-article:16565562 | pubmed:meshHeading | pubmed-meshheading:16565562... | lld:pubmed |
| pubmed-article:16565562 | pubmed:meshHeading | pubmed-meshheading:16565562... | lld:pubmed |
| pubmed-article:16565562 | pubmed:meshHeading | pubmed-meshheading:16565562... | lld:pubmed |
| pubmed-article:16565562 | pubmed:meshHeading | pubmed-meshheading:16565562... | lld:pubmed |
| pubmed-article:16565562 | pubmed:meshHeading | pubmed-meshheading:16565562... | lld:pubmed |
| pubmed-article:16565562 | pubmed:meshHeading | pubmed-meshheading:16565562... | lld:pubmed |
| pubmed-article:16565562 | pubmed:meshHeading | pubmed-meshheading:16565562... | lld:pubmed |
| pubmed-article:16565562 | pubmed:meshHeading | pubmed-meshheading:16565562... | lld:pubmed |
| pubmed-article:16565562 | pubmed:meshHeading | pubmed-meshheading:16565562... | lld:pubmed |
| pubmed-article:16565562 | pubmed:meshHeading | pubmed-meshheading:16565562... | lld:pubmed |
| pubmed-article:16565562 | pubmed:meshHeading | pubmed-meshheading:16565562... | lld:pubmed |
| pubmed-article:16565562 | pubmed:meshHeading | pubmed-meshheading:16565562... | lld:pubmed |
| pubmed-article:16565562 | pubmed:meshHeading | pubmed-meshheading:16565562... | lld:pubmed |
| pubmed-article:16565562 | pubmed:meshHeading | pubmed-meshheading:16565562... | lld:pubmed |
| pubmed-article:16565562 | pubmed:year | 2006 | lld:pubmed |
| pubmed-article:16565562 | pubmed:articleTitle | Comparison of nifekalant and lidocaine for the treatment of shock-refractory ventricular fibrillation. | lld:pubmed |
| pubmed-article:16565562 | pubmed:affiliation | Division of Critical Care and Emergency Medicine, Yokohama City University Medical Center, Japan. | lld:pubmed |
| pubmed-article:16565562 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:16565562 | pubmed:publicationType | Comparative Study | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16565562 | lld:pubmed |
